HopeStage
Back to all studies
CompletedNCT01972711

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

Medication studyAges 18–45United KingdomSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 45 years.

Listed locations
Headington and 1 more locationSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2014
Recruitment status
Completed
Enrollment listed in the registry
105
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 45 Years
Official registry ID
NCT01972711
Official title
Show the full official title

A Randomized, Double-blind, Placebo-controlled, Single-dose, Study of the Effects of SEP 363856 and Amisulpride on BOLD-fMRI Signal in Healthy Male and Female Volunteers With High or Low Schizotype Characteristics.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Headington · Manchester

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including SEP-363856, Amisulpride and Placebo.

Who was this study for?

Listed age limits: 18 years to 45 years.

Want to explore more studies?

Explore studies